Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Zenas BioPharma presented new Phase 3 INDIGO data on obexelimab in IgG4-related disease at the 6th International Symposium on IgG4-Related Disease. Open-label extension data showed a 12-month flare-free probability of 0.93 (adjudicated), and a sub-analysis found obexelimab significantly reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI difference -11.4; p=0.021). A vaccine sub-study found 86% influenza and 100% COVID-19 seroimmunity following vaccination during a treatment-free window, with no disease flares observed.
Key figures
- Drug Name
- obexelimab
- Phase Of Trial
- Phase 3
- Gti p value
- 0.021
- Covid19 seroimmunity
- 4 of 4 (100%)
- Influenza seroimmunity
- 6 of 7 (86%)
- Flare free probability 12mo adjudicated
- 0.93
- Flare free probability 12mo investigator
- 0.87
- Gti cumulative worsening score difference
- -11.4
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.